View Post

FDA Supports Continued Development of Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metastatic breast cancer. Athenex, Inc. held a Type A meeting with the FDA to discuss …